Dolutegravir plus darunavir maintains viral suppression without NRTIs
Reaching the men: who are the partners of the young women with HIV in South Africa?
Prolonged HIV suppression is possible using ibalizumab, analysis of highly drug-resistant people shows
How safe is PrEP? Meta-analysis finds no increased risk of serious side-effects
Hepatitis C increases the risk of premature delivery for pregnant women with HIV
Dolutegravir or lower-dose efavirenz equally effective, but less resistance with dolutegravir
Going local – prevention conference hears about rings, douches, and soluble suppositories
Beyond Truvada – what is the future of PrEP?
Bictegravir matches dolutegravir in first-line treatment
